Skip to: Content
Skip to: Site Navigation
Skip to: Search

October 11, 2008 4:01:39 AM CDT

Learn about Newser Points »

Stories related to: Avandia

Stories

10 Stories

  • June 2008

    • 8 Meds Docs Won't Take

      Men's Health  |  Jun 23, 08 7:55 PM CDT

      8 Meds Docs Won't Take

      (Newser) - Some drugs have such serious drawbacks that even doctors won’t take them, Men’s Health reports. The big eight: Advair: Can actually increase the severity of asthma attacks Avandia: Diabetes drug carries risk of heart attack More »

      Tags

      drugs  • doctor  • prescription drugs  • opinion  • medical treatment  • methamphetamine  • Avandia  • over-the-counter drugs

  • April 2008
  • November 2007

    • Diabetes Drug Given Strictest Warning Label

      Wall Street Journal  |  Nov 14, 07 3:20 PM CST

      Diabetes Drug Given Strictest Warning Label

      (Newser) - The FDA has applied its harshest warning to the diabetes drug Avandia, declaring the product potentially increases risk of heart attacks. Now marked with a “black box” warning, GlaxoSmithKline’s drug will stay on the market pending a continuing “safety assessment,” the Wall Street Journal reports; FDA officials say the agency remains split on the wisdom of pulling the drug immediately. More »

      Tags

      FDA  • diabetes  • GlaxoSmithKline  • Avandia  • black box  • Actos

  • July 2007

    • FDA Panel Votes to Keep Avandia on Shelves

      Wall Street Journal  |  Jul 30, 07 5:38 PM CDT

      FDA Panel Votes to Keep Avandia on Shelves

      (Newser) - An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes drugs. More »

      Tags

      health  • drugs  • FDA  • safety  • diabetes  • GlaxoSmithKline  • Avandia  • heart failure

    • Dow Sinks Further on Credit Jitters

      Wall Street Journal  |  Jul 27, 07 4:10 PM CDT

      Dow Sinks Further on Credit Jitters

      (Newser) - Stocks tumbled more than 200 points for the second day in a row, on fears that small-cap securities might be especially hard hit by a possible collapse in certain financial services. The Dow was down 208.10 to 13265.47, despite a report that the GDP grew faster this quarter than it has in a year—but the Russell 2000, which measures small stocks, dipped 1.7% into negative territory for the year. More »

      Tags

      S&P 500  • Nasdaq  • Wall Street  • FDA  • stocks  • GDP  • GlaxoSmithKline  • Avandia

  • June 2007

    • Controversy Rages Over Diabetes Drug's Heart Risks

      New York Times  |  Jun 6, 07 12:16 PM CDT

      Controversy Rages Over Diabetes Drug's Heart Risks

      (Newser) - Troubling questions about the diabetes drug Avandia persisted yesterday as an FDA official revealed that she was barred from recommending a critical warning about the medication, the Times reports. In the run-up to congressional hearings that began today, manufacturer GlaxoSmithKline rushed to disseminate interim clinical findings in hopes of blunting the controversy. More »

      Tags

      health  • medicine  • FDA  • diabetes  • heart attack  • heart  • GlaxoSmithKline  • Avandia

  • May 2007

10 Stories

Today's Most Popular

Loading...

Premium Articles from HighBeam

Find more articles like this

What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »